HASPIN kinase inhibitor CHR-6494 suppresses intestinal polyp development, cachexia, and hypogonadism in Apcmin/+ mice.
Adenomatous Polyposis Coli Protein
/ physiology
Animals
Cachexia
/ drug therapy
Female
Hypogonadism
/ drug therapy
Indazoles
/ pharmacology
Intestinal Neoplasms
/ drug therapy
Intestinal Polyps
/ drug therapy
Intracellular Signaling Peptides and Proteins
/ antagonists & inhibitors
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Protein Serine-Threonine Kinases
/ antagonists & inhibitors
Pyridazines
/ pharmacology
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
14
12
2019
medline:
31
8
2021
entrez:
14
12
2019
Statut:
ppublish
Résumé
HASPIN has been identified as a nuclear Ser/Thr kinase specifically expressed in haploid germ cells. HASPIN kinase inhibitors were recently isolated, and their antitumor activity reported. Colorectal cancer occurs with high incidence worldwide. In this study, we examined whether HASPIN inhibitor CHR-6494 suppresses cancer progression in Apc mice, a familial colon tumor disease model. Mice were treated by intraperitoneal injection of CHR-6494 for 50 days. Following the treatment period, intestinal polyps were counted and testosterone and spermatogenesis levels were observed. Intraperitoneal administration of CHR-6494 significantly inhibited intestinal polyp development and recovered body weight in Apc mice. Although spermatogenesis was inhibited with increasing age in Apc mice, CHR-6494 significantly improved blood testosterone levels and spermatogenesis. Our results suggest that HASPIN inhibitors may be useful as anti-cancer agents and for the treatment of hypogonadism in colorectal cancer patients.
Identifiants
pubmed: 31833958
doi: 10.1097/CEJ.0000000000000562
pmc: PMC7531494
pii: 00008469-202011000-00001
doi:
Substances chimiques
3-(1H-indazol-5-yl)-N-propylimidazo(1,2-b)pyridazin-6-amine
0
Adenomatous Polyposis Coli Protein
0
Haspin protein, mouse
0
Indazoles
0
Intracellular Signaling Peptides and Proteins
0
Pyridazines
0
adenomatous polyposis coli protein, mouse
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-485Références
Int J Mol Sci. 2017 Oct 24;18(10):
pubmed: 29064398
Carcinogenesis. 2003 Jul;24(7):1219-24
pubmed: 12807720
J Pathol. 2016 Jan;238(2):141-51
pubmed: 26414675
Cell Cycle. 2005 May;4(5):665-8
pubmed: 15846065
Reproduction. 2019 Jun;157(6):501-510
pubmed: 30870811
Chromosoma. 2017 Dec;126(6):769-780
pubmed: 28803373
Cell Discov. 2017 Jan 10;3:16049
pubmed: 28101375
J Biol Chem. 1999 Jun 11;274(24):17049-57
pubmed: 10358056
Biol Open. 2013 Dec 15;2(12):1346-53
pubmed: 24285707
Protein Sci. 2001 Aug;10(8):1677-84
pubmed: 11468364
Development. 2013 Apr;140(8):1751-61
pubmed: 23533175
Nat Commun. 2016 Jul 08;7:12059
pubmed: 27389782
Cancer Res. 2007 May 1;67(9):4079-87
pubmed: 17483318
Sci Rep. 2018 Apr 3;8(1):5424
pubmed: 29615651
Int J Exp Pathol. 2006 Jun;87(3):227-36
pubmed: 16709231
Oncogene. 2012 Mar 15;31(11):1408-18
pubmed: 21804608
Mol Hum Reprod. 2001 Mar;7(3):211-8
pubmed: 11228240
FEBS Lett. 1994 Nov 21;355(1):4-10
pubmed: 7957958
Genes Dev. 2005 Feb 15;19(4):472-88
pubmed: 15681610
Bioorg Chem. 2018 Aug;78:418-426
pubmed: 29698892
Gene. 2001 Apr 4;267(1):55-69
pubmed: 11311556